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Abstract Pyridine nucleotides are mostly stored within mito-
chondria where they are involved in different functions ranging
from energy metabolism to cellular signaling. Here we discuss
the mechanisms of mitochondrial NAD metabolism and release
that may contribute to the crucial roles played by these
organelles as triggers or amplifiers of physiological and
pathological events. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
The pyridine nucleotides serve two important functions in
the cell. They are coenzymes in the majority of metabolic
redox reactions and thus are essential for energy transduction.
On the other hand, in a number of signaling pathways
NAD(P) is used to form potent calcium-mobilizing agents
or as substrate for covalent protein modi¢cation, ADP-ribo-
sylation [1]. This dual function in energy and signal transduc-
tion is also characteristic for ATP. It is not surprising then
that in cells exposed to pathophysiological conditions (e.g.
DNA-damaging agents, ‘oxidative stress’ etc.) the pyridine
nucleotides play an essential role in the mechanisms counter-
acting the potential damage.
A signi¢cant proportion of the cellular NAD pool is com-
partmentalized within the mitochondria [2,3]. Several lines of
evidence suggest that NAD-dependent signaling events may
occur in mitochondria. This review will summarize these ob-
servations and also focus on the pathophysiological implica-
tions of these processes, speci¢cally in the heart.
2. Pathways of NAD+ metabolism
As pointed out above, the synthetic routes of NAD(P)
lead to the formation of an essential energy transducing mol-
ecule and precursors of signaling pathways. Therefore, it
should be expected that NAD(P) synthesis reactions are
well controlled. Surprisingly, little is known about the regu-
lation of NAD(P) formation [4]. Moreover, although the
pathways of NAD(P) generation have been established a
long time ago, several enzymes have not been characterized
on a molecular level. For example, the amino acid sequence of
the human nicotinamide mononucleotide adenylyltransferase
(NMNAT) has been established only very recently [5,6] as the
¢rst primary structure from higher eukaryotes. No sequence
information is available for NAD kinase from any organism.
NMNAT and NAD kinase appear to be essential, because
they catalyze the only known anabolic reactions in which
NAD and NADP, respectively, are formed.
The sources of mitochondrial NAD and NADP are un-
known. The inner membrane of mammalian mitochondria is
normally impermeable to pyridine nucleotides. The only fea-
sible possibility to enter the mitochondria would be through
the permeability transition pore (PTP, see below). Alterna-
tively, the ¢nal steps of NAD and NADP synthesis should
be catalyzed within the organelles. However, NMNAT was
localized exclusively to the nucleus [6], although a mitochon-
drial isoform may exist [7]. A mitochondrial NAD kinase
activity has not been reported, whereas it is well known that
NADH and NADPH are linked through the activity of the
energy-linked transhydrogenase [8].
The degradation of NAD(P) has been a major ¢eld of
investigation over the last few years, because several routes
are now known to carry signaling functions (Fig. 1). These
reactions have in common the cleavage of the glycosidic bond
between the nicotinamide moiety and the terminal ribose of
NAD. In its simplest form this would be hydrolysis of
NAD to ADP-ribose and nicotinamide catalyzed by
NAD glycohydrolases (NADases). These enzymes have
been known for long and were initially regarded as purely
catabolic. However, it has been found that a second product
of the reaction is cyclic ADP-ribose (cADPR) in which a bond
is formed between the terminal ribose and the N1 of the ad-
enine ring, again under release of nicotinamide [9]. Therefore,
NADases have also been termed ADP-ribosyl cyclases. It is
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now well established that cADPR represents an important
intracellular messenger which releases calcium from the ER.
ADP-ribosyltransferases use NAD to attach the ADP-ri-
bose moiety to proteins. This protein modi¢cation is reversed
by hydrolases leading to the liberation of ADP-ribose. There-
fore, ADP-ribose appears to be the major catabolite of
NAD. ADP-ribose itself does not appear to exert any bio-
logical activity. Presumably, these pathways of NAD degra-
dation are tightly controlled owing to their signaling func-
tions. In addition, the resynthesis of NAD from ADP-
ribose and nicotinamide requires as many as four molecules
of ATP [10].
NAD may also be cleaved by pyrophosphatase(s), e.g.
phosphodiesterase I, to AMP and NMN. The physiological
signi¢cance of this pathway is unknown. Moreover, the re-
verse reaction of NMNAT (NAD+PPiCATP+NMN) may
be regarded as a catabolic route which would permit a direct
conversion of NAD into ATP. In the nucleus an analogous
pathway has been described that makes use of ADP-ribose
(and pyrophosphate) instead of NAD to form ATP and
ribose phosphate [11]. This reaction appears to be an impor-
tant source of ATP required for the ligation step in DNA
repair [11].
3. NAD(P)+-dependent signaling pathways
The known mechanisms of NAD-dependent signaling ap-
pear to be widely conserved in living organisms. Enzymes that
catalyze the synthesis of cADPR or monoADP-ribosylation
have been found in prokaryotes and eukaryotes (reviewed in
[1]). However, the biological roles of these reactions are still
far from being understood. Poly(ADP-ribosyl)ation appears
to be restricted to the nucleus and is, therefore, limited to
eukaryotes. It is important to point out that all NAD-medi-
ated signaling pathways use only the oxidized form of the
pyridine nucleotides, NAD(P).
3.1. Mono- and poly(ADP-ribosyl)ation
Over the past years the cloning of several monoADP-ribo-
syl transferases (ART) as well as the corresponding hydrolases
from mammalian and avian tissues [12] has clearly supported
the potential importance of this posttranslational protein
modi¢cation. However, owing to the diversity of identi¢ed
putative acceptor proteins it is still di⁄cult to recognize a
general principle that underlies regulation by monoADP-ribo-
sylation. In addition, the majority of transferases and hydro-
lases identi¢ed have been localized to the outer surface of the
plasma membrane.
The role of poly(ADP-ribosyl)ation has been established to
be related to vital cellular events such as DNA repair, tran-
scription, and apoptosis, [13^15] but also to the regulation of
telomere length [16] and of sister chromatid exchange [17].
The major enzyme catalyzing the reaction is strongly activated
by DNA single strand breaks. Recent evidence suggests that
poly(ADP-ribose) may serve as the source of ATP for the
ligation step in base excision DNA repair [11]. Moreover,
previous reports have documented that poly(ADP-ribosyl)-
ation may consume virtually all cellular NAD, if induced
by genotoxic treatment [18].
3.2. Calcium-mobilizing derivatives of NAD(P)+
As pointed out above, NADases are capable of forming
cADPR. In a large number of investigations cADPR has
been documented to trigger calcium release from the endo-
plasmic reticulum (reviewed in [19]). The calcium is apparent-
ly released via ryanodine receptors. Evidence has been pre-
sented that cADPR- and inositol-1,4,5-trisphosphate (InsP3)-
dependent calcium release pathways are redundant [20], but
also that they may be activated during di¡erent phases of
intracellular calcium signaling pathways [21].
The NADases have also been shown to carry out a trans-
glycosidation reaction leading to the replacement of nicotin-
amide by nicotinic acid in NADP [22]. The resulting mole-
cule, nicotinic acid adenine dinucleotide phosphate (NAADP),
also represents a highly potent calcium-mobilizing agent (re-
viewed in [19]). Interestingly, NAADP appears to activate
calcium stores that are di¡erent from those activated by
cADPR or InsP3 [19].
NADase/ADP-ribosyl cyclase activities have been reported
in heart and liver mitochondria [3,23^26], nuclei [27] and plas-
ma membrane [19]. However, in higher eukaryotes including
mammals, no intracellular NADase/ADP-ribosyl cyclase has
been cloned so far. The only identi¢ed mammalian enzymes of
this type (CD38 and BST-1) are localized to the outer surface
of the plasma membrane [19]. The recent identi¢cation of
connexin-43 as a bidirectional transport system for pyridine
nucleotides across the plasma membrane [28] indicates a po-
tential pathway permitting both the access of intracellular
NAD to the ectoenzyme and the cellular uptake of cADPR.
4. NAD+ and mitochondria
A substantial fraction of the cellular NAD pool (about
75% in heart muscle) is compartmentalized within the mito-
chondria [2,3]. It is now well established that in isolated mi-
tochondria NAD can be utilized for monoADP-ribosylation
and the synthesis of cADPR [1]. Importantly, the reduced
form [NAD(P)H] is not a substrate for any of the
NAD(P)-dependent signaling pathways. Accordingly, ADP-
ribosylation and synthesis of cADPR are triggered under ox-
idizing conditions resembling ‘oxidative stress’ [26].
The precise location of the enzymes catalyzing the produc-
tion or the consumption of pyridine nucleotides, that is,
whether the various activities are present within the matrix
or outside the inner membrane, is still in debate.
Scarce information is available about the mechanism(s) that
supply mitochondria with NAD(P). NMNAT activity has
been reported for the matrix of liver mitochondria [7] and
an NADH kinase activity has been detected in yeast mito-
chondria [29].
Under physiological conditions, in both isolated mitochon-
dria and intact cells the matrix content of NAD is stable
[3,30,31] and is not in£uenced by changes in ATP concentra-
tions which a¡ect the cytosolic levels of NAD, probably by
modulating the activity of NADase [31]. On the other hand,
results from a classic study on isolated mitochondria demon-
strate that NAD content becomes rapidly depleted upon
Ca2 addition [30]. Such a process has been recently ascribed
to the opening of the PTP [3], a high conductance channel
located in the inner mitochondrial membrane (IMM) [32]. The
opening of PTP causes a Ca2-dependent increase of mito-
chondrial permeability to ions and solutes with molecular
weights up to 1500 Da, matrix swelling and collapse of mito-
chondrial membrane potential (vim). Cyclosporin A (CsA), a
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high a⁄nity inhibitor of PTP, completely prevents both the
swelling and the subsequent hydrolysis of NAD in rat heart
and liver mitochondria added with Ca2 [3]. In the same study
it was shown that the NADase activity of isolated mitochon-
dria is not modi¢ed by CsA or Triton X-100. On the other
hand, the activity was eliminated by treatment with Nagarse,
a serine protease commonly used to extract heart mitochon-
dria [33] which does not a¡ect the intactness of the IMM.
These indirect lines of evidence support the localization of
NADase in the outer mitochondrial membrane. Thus, a mod-
el emerges whereby upon PTP opening NAD may be released
from the mitochondrial matrix to the intermembrane space
becoming a substrate of NADase (Figs. 1 and 2). Besides
Ca2, such a process could be favored by oxyradicals that
promote PTP opening [32,34] and stimulate the activity of
NADase [26]. In addition, NAD hydrolysis could be further
enhanced by a more oxidized state of pyridine nucleotides
caused by the uncoupling of oxidative phosphorylation as a
consequence of the collapse of the membrane potential.
Previous reports, which ¢rstly highlighted the relationship
between oxidative stress and NAD hydrolysis, suggested that
ADP-ribose produced by a CsA-inhibitable mitochondrial
glycohydrolase would be utilized for the non-enzymatic
monoADP-ribosylation of an intrinsic protein of the inner
membrane [35^37]. Such a mechanism, which would eventu-
ally result in the stimulation of a speci¢c e¥ux pathway for
Ca2, has been challenged by recent reports [3,24]. Indeed,
besides the lack of glycohydrolase inhibition by CsA, PTP
opening, and thus Ca2 e¥ux, precedes and is necessary for
NAD hydrolysis. Moreover, mitochondrial ADP-ribosyla-
tion has been demonstrated to be enzyme-catalyzed, that is,
independent of the activity of an NADase [38,39].
The fate of NAD after PTP opening is determined by the
action of many enzymes that can be grouped into three major
pathways (Fig. 1). Far from being mutually exclusive, these
modes of NAD utilization are closely related, so that the
prevalence of one pathway over the others will result from
other cellular events that in part will be discussed in Section
5. Under conditions of ATP depletion the formation of ADP-
ribose and nicotinamide or AMP can be considered a degra-
dative pathway, since these metabolites cannot be used di-
rectly for NAD resynthesis. Moreover, ADP-ribose may be
further degraded to AMP and ribose phosphate by a matrix
pyrophosphatase [40]. In the recovery pathway ATP might be
generated from ADP-ribose by means of a reaction similar to
that described above for the nucleus. Finally, the signaling
pathways comprise the cyclase reactions and the covalent
modi¢cation of proteins by means of ADP-ribosylation.
Beside the pathological relevance of PTP in NAD metabo-
lism discussed below, the opening of PTP might mediate bi-
directional £uxes of NAD through the IMM which was ob-
served in digitonin-treated cell lines [41]. The passage of
NAD through IMM contrasts with the accepted notion of
the lack of permeability of this membrane for pyridine nucleo-
tides. The transient and reversible opening of PTP [42], which
has been proposed to act physiologically as a Ca2 release
channel [43], could allow NAD tra⁄cking and turnover
within the cell. It should be noted, however, that despite the
numerous observations compatible with the occurrence of the
PTP, the isolation and characterization of the constituents of
the PTP are still required to elucidate the biochemical mech-
anisms conclusively.
5. Mitochondrial NAD+ in injured cells
The relevance of PTP in NAD metabolism and fate is
highlighted by post-ischemic reperfusion of myocardium [3].
In fact, mitochondrial NAD content, which is hardly af-
fected during ischemia, becomes almost depleted when coro-
nary £ow is restored after a prolonged period of ischemia. The
inhibition of mitochondrial NAD depletion exerted by CsA
suggests that upon reperfusion the rise in intracellular Ca2
([Ca2]i), along with the recovery of neutral pH and the
boosting of oxyradical generation [44], promotes PTP opening
causing the release of intramitochondrial NAD and its sub-
sequent hydrolysis. Not only is the decrease of mitochondrial
NAD prevented when PTP is inhibited, but also tissue via-
bility is signi¢cantly protected, as documented in di¡erent
experimental models [3,45^47]. The protection a¡orded by
CsA is mimicked by N-methylvaline-4-cyclosporin, a cyclo-
sporin derivative that binds cyclophilins and inhibits the
PTP but does not a¡ect calcineurin activity [3,48]. Thus, a
direct action on mitochondria results in myocyte protection
indicating that PTP opening represents a key step in the rapid
sequence of events that eventually results in the loss of sarco-
lemma integrity.
Besides a¡ecting energy metabolism, the mitochondrial re-
lease of NAD is likely to modify several intracellular pro-
cesses triggered by ischemia or other pathological conditions.
Indeed, once released out of the mitochondrial matrix, NAD
could be transformed into cADPR which promoting Ca2
release from intracellular stores may amplify and extend the
Fig. 1. Possible metabolic pathways of NAD released from mito-
chondria. Under physiological conditions a major fraction of the
cellular NAD is stored within the matrix space. The opening of
the mitochondrial PTP, a large channel located within IMM, in-
duces a profound decrease of mitochondrial NAD. The degrada-
tion pathway and the generation of cyclic nucleotides are likely to
occur outside of the matrix space which, on the other hand, might
be a site for ADP-ribosylation and reactions resulting in the recov-
ery of both ATP and NAD. The numbers indicate the following
enzymes: 1, NADase/ADP-ribosyl cyclase; 2, ART; 3, PARP; 4,
nucleotide pyrophosphatase; 5, NMNAT; 6, ART. cADPRP,
cADPR phosphate; GSH, reduced glutathione; GSSG, oxidized glu-
tathione, NMN, nicotinamide mononucleotide; PPi, pyrophosphate;
PARP, poly(ADP-ribosyl) polymerase; ROS, reactive oxygen spe-
cies.
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e¡ects exerted by an initial rise in [Ca2]i (Fig. 2). Thus, the
release of NAD from mitochondria and its subsequent uti-
lization within other cell compartments could be part of the
mechanisms through which mitochondria transduce and am-
plify an initial trigger provided by reperfusion [49].
That is, the relationship between NAD and ATP is not
limited to mitochondria, but also concerns other cellular sites
(Fig. 2). For instance in the ischemic heart, as well as in other
pathological states, NAD has been reported to be actively
utilized within the nucleus as a consequence of poly(ADP-
ribose) polymerase (PARP) activation [18,50]. It has been
proposed that subsequent NAD resynthesis causes the deple-
tion of ATP [18]. According to this suggestion (i) the deple-
tion of NAD should precede that of ATP; (ii) the depletion
of ATP would not require mitochondrial derangements; (iii)
PARP should have access to the entire cellular NAD. It
appears, however, that mitochondrial contributions have to
be taken into account when considering the depletion of
NAD or ATP.
The assumption that PARP activity alone is su⁄cient to
drain the entire content of cellular NAD implies the con-
sumption of the mitochondrial pool which is the largest of
the cell. The utilization of NAD by PARP within the nucleus
clearly requires the mobilization of mitochondrial NAD,
which in turn would depend on a release pathway. Transient
openings of PTP are perfectly reversible and might be impor-
tant for mitochondrial ionic homeostasis and intracellular sig-
naling [42,47,51]. Conversely, a prolonged opening of PTP
results in vim collapse and ATP hydrolysis, conditions which
have been consistently documented in experimental and clin-
ical settings of myocardial ischemia [49,52]. Thus, NAD and
ATP are not likely to be depleted without a concomitant,
perhaps causative, alteration of mitochondrial function. Ac-
cordingly, the depletion of ATP does not require a preceding
fall in NAD content. Mitochondrial derangements are likely
to exert a substantially greater impact on ATP depletion than
that of the presumed requirement for NAD resynthesis. In
fact, under conditions leading to ATP depletion NAD might
be used as an emergency source for ATP synthesis. It has been
observed that in the nucleus poly(ADP-ribose) (synthesized
from NAD) may serve to generate ATP which is speci¢cally
used for DNA repair [11]. Conversely, high levels of ATP
prevent poly(ADP-ribosyl)ation and are su⁄cient for e⁄cient
DNA repair. This implies that poly(ADP-ribosyl)ation is trig-
gered only after ATP depletion which most likely results from
mitochondrial derangements.
In conclusion, the relationship between mitochondria and
pyridine nucleotides extends far beyond the role of anaerobic
dehydrogenases in oxidative metabolism. Besides being the
major reservoir of the cellular NAD(P), mitochondria also
represent a site of active pyridine nucleotide metabolism as
indicated by the generation of signaling molecules and protein
ADP-ribosylation. The molecular characterization of mito-
chondrial enzymes and transporters involved in pyridine nu-
cleotide metabolism will further de¢ne the relevance of the
mitochondrial contribution to the overall NAD(P) turnover
in the cell and will facilitate the development of novel ther-
apeutic approaches.
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